|
Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we report the chromosomal mapping of two cdks, cdk3 and cdk6, two putative cdks, PISSLRE and PITALRE, and one cyclin-dependent kinase inhibitor, p27, to chromosomal regions which may be altered in human tumors and examine their possible involvement in some of these malignancies.
|
7882308 |
1995 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
p16INK4A, a specific inhibitor of cyclin-dependent kinase (cdk)4 and cdk6, is a candidate tumor suppressor in malignancies with wild-type retinoblastoma (Rb).
|
8521414 |
1995 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data implicate the CDK6 gene in genomic amplification and illustrate the potential of RLGS for the more general identification and cloning of novel genes that are amplified in human cancer.
|
9102208 |
1997 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Rb phosphorylation is mediated by cyclin-dependent kinases (CDKs), whose activity is enhanced by cyclins and inhibited by CDK inhibitors. p16(INK4A) is a member of a family of inhibitors specific for CDK4 and CDK6. p16(INK4A) is deleted and inactivated in a wide variety of human malignancies, including familial melanomas and pancreatic carcinoma syndromes, indicating that it is an authentic human tumor suppressor.
|
11325039 |
2000 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
p16INK4a, a cell cycle inhibitor that inhibits cyclin-dependent kinase 4 (cdk4) and cdk6, has been found as the tumor suppressor gene and is frequently deleted, methylated or mutated in many malignancies.
|
15138605 |
2004 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Finally, we suggest that the aberrant activation of Cdk6 in E47-deficient T lineage cells contributes to the development of lymphoid malignancy.
|
16782810 |
2006 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Gains/losses and gene expression profiles show strong similarity between cancers in the distal esophagus and the gastroesophageal junction with frequent upregulation of CDK6 and EGFR, whereas gastric cancer displays distinct genetic changes.
|
20620594 |
2010 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recently, cyclin-dependent kinase 6 (CDK6) is found to be up-regulated in several types of human tumors and has been implicated in cancer initiation and progression.
|
21264532 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This role of CDK6 as a downstream mediator of Notch identifies CDK6 kinase activity as a potential therapeutic target in human lymphoid malignancies.
|
21508411 |
2011 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Reversible inhibition of CDK4/CDK6 in sequential combination therapy thus represents a novel mechanism-based cancer therapy.
|
22718837 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that CDK6, a cell cycle regulator, is significantly upregulated in glioma cells, and the increasing expression of CDK6 correlates well with the grades of glioma malignancy.
|
22736304 |
2012 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Detected alterations comprised chromosomal copy number changes and rearrangements, including amplification of cancer driver genes such as ERBB2 and CDK6.
|
23197571 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high levels in lymphoid malignancies.
|
23948297 |
2013 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This interaction suggests that CDK6 regulates EYA2 activity, a mechanism that could be important in development and in cancer.
|
24196439 |
2014 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies.
|
24726269 |
2014 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Three miR-124a genes were methylated in all neoplastic tissues (CAC, dysplasia, and S-CRC), and CDK6 was highly expressed in those tissues.
|
24825593 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we show that CDK6 is modified by small ubiquitin-like modifier-1 (SUMO1) in glioblastoma, and that CDK6 SUMOylation stabilizes the protein and drives the cell cycle for the cancer development and progression.
|
24953629 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting CDK4/CDK6 in combination with cytotoxic killing therefore represents a rational approach to cancer therapy.
|
25744718 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
On the other hand, a recent study revealed that miR-504 inhibits cancer cell proliferation through targeting CDK6 in hypopharyngeal squamous cell carcinoma (HSCC), suggesting the tumor suppressive role of this miRNA.
|
25755767 |
2015 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The cyclin-dependent kinase 6 (CDK6) gene, which plays an important role in cancer pathways, was found to be differentially expressed between brainstem and thalamic gliomas with K27M mutations.
|
26297251 |
2015 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<i>Cdk6</i>-deficient cells are sensitive to drugs that interfere with the cytoskeleton, suggesting that our findings are relevant to the treatment of patients with anemia - and may be relevant to cancer patients treated with the new generation of CDK6 inhibitors.
|
28255017 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, Ki-67 expression varies due to cell-cycle regulation, but it remains a reliable readout for effects of CDK4/CDK6 inhibitors on cell proliferation.<i>Cancer Res; 77(10); 2722-34.©2017 AACR</i>.
|
28283655 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results.
|
28607489 |
2017 |